The search for a vaccine for the dreaded Ebola virus continues and this week at the National Institutes of Health, trial tests on a set of human specimen will begin.
Director of the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Anthony Fauci has said that the go ahead has been proferred researchers to begin what is to be called safety trials, after an expedited review by the U.S. Food and Drug Administration.
Accordingly it will be tested on healthy persons to check for adverse effects, after which if deemed safe, will be tested on another small group of volunteers aged 18 to 50, to see if it produces a strong immune response to the virus.
It will be the first test of this type of Ebola vaccine in humans. The experimental vaccine was developed by GlaxoSmithKline and the NIAID.
